The estimated Net Worth of John W Childs is at least $95.4 Million dollars as of 18 July 2024. Mr. Childs owns over 28,400 units of Biohaven Ltd stock worth over $83,575,549 and over the last 7 years he sold BHVN stock worth over $11,067,000. In addition, he makes $734,433 as Director at Biohaven Ltd.
Sign up
Mr. Childs BHVN stock SEC Form 4 insiders trading
John has made over 22 trades of the Biohaven Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 28,400 units of BHVN stock worth $1,013,028 on 18 July 2024.
The largest trade he's ever made was buying 3,900,000 units of Biohaven Ltd stock on 25 October 2022 worth over $40,950,000. On average, John trades about 190,991 units every 77 days since 2017. As of 18 July 2024 he still owns at least 2,339,741 units of Biohaven Ltd stock.
You can see the complete history of Mr. Childs stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Childs biography
John W. Childs serves as Director of the Company. Mr. Childs has served as a director of our Company since January 2014. Mr. Childs served as chairman and partner of J.W. Childs Associates, L.P., a private equity firm, from 1995 to 2019. From 1991 to 1995, Mr. Childs was senior managing director of Thomas H. Lee Partners and from 1987 to 1990 was a managing director of Thomas H. Lee Partners. Prior to 1987, Mr. Childs was associated with the Prudential Insurance Company of America (“Prudential”) for 17 years where he held various executive positions in the investment area, ultimately serving as senior managing director in charge of the Capital Markets Group, at which time he was responsible for Prudential’s approximately $77 billion fixed income portfolio, including all of the Capital Markets Group’s investments in leveraged acquisitions. He is currently a director of Realm Cellars, Omax Health Inc., Kleo Pharmaceuticals, Inc., and is on the Board of Managers of the Jane Coffin Childs Memorial Fund for Medical Research. Mr. Childs holds a B.A. from Yale University and an MBA from Columbia University.
What is the salary of John Childs?
As the Director of Biohaven Ltd, the total compensation of John Childs at Biohaven Ltd is $734,433. There are 10 executives at Biohaven Ltd getting paid more, with Vlad Coric having the highest compensation of $6,787,630.
What's John Childs's mailing address?
John's mailing address filed with the SEC is C/O BIOHAVEN LTD., 215 CHURCH STREET, NEW HAVEN, CT, 06510.
Insiders trading at Biohaven Ltd
Over the last 8 years, insiders at Biohaven Ltd have traded over $8,186,598,135 worth of Biohaven Ltd stock and bought 8,852,002 units worth $137,738,037 . The most active insiders traders include Robert J Hugin, John W Childs, and Declan Doogan. On average, Biohaven Ltd executives and independent directors trade stock every 14 days with the average trade being worth of $2,840,776. The most recent stock trade was executed by John W Childs on 18 July 2024, trading 28,400 units of BHVN stock currently worth $1,013,028.
What does Biohaven Ltd's logo look like?
Complete history of Mr. Childs stock trades at Biohaven Ltd
Biohaven Ltd executives and stock owners
Biohaven Ltd executives and other stock owners filed with the SEC include:
-
Vlad Coric,
Chief Executive Officer, Director -
William Jones,
Chief Commercial Officer, Migraine and Common Diseases -
Charles Conway,
Chief Scientific Officer -
Kimberly Gentile,
Senior Vice President - Clinical Operations -
James Engelhart,
Chief Financial Officer, Treasurer -
Elyse Stock,
Chief Medical Officer -
John Tilton,
Chief Commercial Officer, Rare and Orphan Diseases -
Dr. Vladimir Coric M.D.,
Chairman, CEO & Pres -
William Jones M.B.A.,
Chief Commercial Officer of Migraine & Common Diseases -
Julia Gregory,
Independent Director -
John Childs,
Director -
Gregory Bailey,
Director -
Dr. Elyse Stock M.D.,
Chief Medical Officer -
Kimberly Gentile,
Sr. VP of Clinical Operations -
Robert Berman,
Lead - Special Projects and Medical Oversight -
Robert Hugin,
Director -
Michael Heffernan,
Director -
Thomas Lynch,
Chairman of the Board -
Clifford Bechtold M.S.,
Pres & GM of Biohaven Ireland and Chief Compliance Officer -
Wendy Goss,
Exec. Admin. Assistant -
Dr. Charles Conway,
Chief Scientific Officer -
George C. Clark,
VP & Chief Accounting Officer -
Matthew DeLawder,
Director of Accounting -
Matthew Buten,
Chief Financial Officer -
Albert Cha,
Director -
Robert Repella,
Director -
Eric Aguiar,
-
Biotech Inc. Portage,
-
Declan Doogan,
-
Irina Antonijevic,
-
Kishan Mehta,
-
George C. Clark,
VP, Chief Accounting Officer -
Matthew Buten,
Chief Financial Officer -
Pharmaceutical Holding Co L...,
-
Bruce Car,
Chief Scientific Officer